$1.41
2.17% day before yesterday
Nasdaq, Oct 03, 10:02 pm CET
ISIN
US5288723027
Symbol
LXRX

Lexicon Pharmaceuticals, Inc. Stock price

$1.41
+0.33 30.56% 1M
+0.97 218.14% 6M
+0.67 90.93% YTD
-0.20 12.42% 1Y
-1.04 42.45% 3Y
-0.01 0.35% 5Y
-10.60 88.26% 10Y
-26.94 95.03% 20Y
Nasdaq, Closing price Fri, Oct 03 2025
+0.03 2.17%
ISIN
US5288723027
Symbol
LXRX
Industry

Key metrics

Basic
Market capitalization
$512.4m
Enterprise Value
$429.5m
Net debt
positive
Cash
$139.0m
Shares outstanding
363.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
8.8 | 9.9
EV/Sales
7.4 | 8.3
EV/FCF
negative
P/B
4.0
Financial Health
Equity Ratio
48.9%
Return on Equity
-137.3%
ROCE
-62.1%
ROIC
-
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$58.4m | $52.0m
EBITDA
$-117.8m | $-79.7m
EBIT
$-118.4m | $-79.5m
Net Income
$-120.6m | $-71.6m
Free Cash Flow
$-102.7m
Growth (TTM | estimate)
Revenue
1,487.8% | 67.2%
EBITDA
40.1% | 59.5%
EBIT
39.9% | 59.7%
Net Income
40.3% | 64.3%
Free Cash Flow
47.7%
Margin (TTM | estimate)
Gross
99.2%
EBITDA
-201.6% | -153.4%
EBIT
-202.6%
Net
-206.4% | -137.8%
Free Cash Flow
-175.7%
More
EPS
$-0.3
FCF per Share
$-0.3
Short interest
21.8%
Employees
103
Rev per Employee
$300.0k
Show more

Is Lexicon Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Lexicon Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:

8x Buy
73%
3x Hold
27%

Analyst Opinions

11 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:

Buy
73%
Hold
27%

Financial data from Lexicon Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
58 58
1,488% 1,488%
100%
- Direct Costs 0.48 0.48
78% 78%
1%
58 58
1,599% 1,599%
99%
- Selling and Administrative Expenses 93 93
32% 32%
159%
- Research and Development Expense 84 84
30% 30%
143%
-118 -118
40% 40%
-202%
- Depreciation and Amortization 0.60 0.60
11% 11%
1%
EBIT (Operating Income) EBIT -118 -118
40% 40%
-203%
Net Profit -121 -121
40% 40%
-206%

In millions USD.

Don't miss a Thing! We will send you all news about Lexicon Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lexicon Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
13 days ago
Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter
Neutral
GlobeNewsWire
18 days ago
Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 and was well tolerated in PROGRESS Phase 2b study Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 and was well tolerated in PROGRESS Phase 2b study
Neutral
GlobeNewsWire
24 days ago
Presentations collectively highlight pilavapadin's potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP)
More Lexicon Pharmaceuticals, Inc. News

Company Profile

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include XERMELO, Zynquista, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Head office United States
CEO Michael Exton
Employees 103
Founded 1995
Website www.lexpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today